AAIFNC 2025 Annual Symposium: Bridges to Understanding

San Francisco, CA US
April 26, 2025

The 2025 Bridges to Understanding program will provide continuing medical education on Food Allergy, COPD and Asthma, Eosinophilic GI Disorders, Atopic Dermatitis, and Immunodeficiency.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Allergy, Asthma & Immunology Foundation of Northern California (AAIFNC).  The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 6.25 contact hours.

No commerical support was received for this activity.

Target Audience

Practicing allergists
Primary care physicians
Allied healthcare professionals

Learning Objectives

At the conclusion of this Activity learners should be able to…
• Select appropriate patients for oral food challenge
• Identify safety precautions necessary for conducting oral food challenge
• Describe recent advances in OIT, SLIT and EPIT
• Identify advantages and disadvantages of all methods of treatment
• Be prepared to discuss advances, expectations and limitations with your food allergic patients
• Describe the cardinal manifestations of immune deficiencies and how to distinguish these immune defects. 
•  Review the treatments used to treat primary Immunodeficiency
• Perform differential diagnosis of eosinophilic disorders
• Discuss management of patients with eosinophilic disorders
• Describe investigational monitoring and treatment options for patients with eosinophilic disorders
• When treating patients with asthma, allergists need to select diagnostic and treatment approaches on the basis of evidence-based practice parameters, expert opinion and recent clinical data.
• Review evolving therapeutic strategies, including inhaled antifungal therapies and biologic medications
• Review clinical data indicating suggesting possible remittive effects of biologics in asthma
• Identify causes of atopic dermatitis
• Describe appropriate and effective testing methods and their role in evaluating atopic dermatitis

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

No commerical support was received for this activity.

Course summary
Available credit: 
  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN
Course opens: 
04/26/2025
Course expires: 
12/31/2026
Event starts: 
04/26/2025 - 10:15am CDT
Event ends: 
04/26/2025 - 6:15pm CDT
Add to calendar: 
Rating: 
5

Allergy, Asthma & Immunology Foundation of Northern California
2025 Annual Symposium: Bridges to Understanding

April 26, 2025

6:15AM-8:15AM

Registration, Exhibits & Coffee Break

 General Sessions - Nikko Ballroom I and II

8:15AM-8:20AM

PROGRAM INTRODUCTION and WELCOME -Steve Machtinger, MD and Kristina Philpott, MD, Moderators

8:20AM-9:05AM

Food Allergy (OIT, SLIT, EPIT) - Edwin Kim, MD, MS

9:05AM-9:50AM

Food Allergy Biologics - Sayantani Sindher, MD

9:50AM-10:35AM

Prevention of Food Allergy - Gideon Lack, MD, MBBCH, FRCP, CH, MA

10:35AM-10:50AM

Food Allergy Q&A

10:50AM-11:20AM

Exhibits, Posters, Coffee Break (Nikko Ballroom III)

11:20AM-12:10PM

Updates on the Diagnosis and Management of Humoral Immune Deficiencies - Kelli Williams, MD, MPH

12:10PM-1:00PM

Eosinophilic GI Disorders (Updates & Management for adults and children) - Seema Aceves, MD, PhD

1:00PM-2:05PM

Lunch Break & Exhibits (Nikko Ballroom III)

2:10PM-3:00PM

COPD/Asthma (Biologics & New Treatments) - Michael E. Wechsler, MD, MMSc

3:00PM-3:50PM

Beyond Our AD Guidelines: New and Emerging Therapies for Atopic Dermatitis - Mark Boguniewicz, MD

3:50PM-4:10PM

Q&A

4:10PM-4:15PM

Acknowledgements & Wrap-Up - Steve Machtinger, MD – AAIFNC President

 

Hotel Nikko
222 Mason St.
San Francisco, CA 94012
United States

All relevant financial relationships with ineligible companies have been mitigated.

Seema Aceves, MD, PhD – Speaker
Advisor: AstraZeneca, Ferring Pharma, Regeneron/Sanofi, Sanofi; Royalties or Patent Beneficiary: Takeda; Speaker: Regeneron/Sanofi

Greg Bensch, MD – Planner
Advisor: Aimmune, AstraZeneca, Dermavant, Sanofi/Regeneron; Consultant: Sanofi/Regeneron; Speaker: Aimmune, AstraZeneca, Blueprint Medicines, Incyte, Sanofi/Regeneron, Teva

Mark Boguniewicz, MD – Speaker
Advisor: AbbVie, Amgen, Arcutis, Astria, Dermavant, Incyte, Leo Pharma, Lilly, Pfizer, Regeneron, Sanofi-Genzyme; Researcher: Incyte, Regeneron, Sanofi

Edwin Kim, MD, MS – Speaker
Advisor: ALK, Cellergy Pharma, Ukko; Consultant: Allakos, DBV Technologies, Genentech, Hanimune Therapeutics, Novartis, Phylaxis Bioscience, Revolo Biotherapeutics

Gideon Lack, MA, MBBCH, FRCP, CH, MD – Speaker
Advisor: ALK Abello, Aravax, DBV Technologies, Novartis; Stock/Stock options: DBV Technologies, Mission MightyMe

Kristina Philpott, MD – Moderator, Planner
Stock/Stock options: Amgen, GSK, Eli Lilly, Illumina, Medtronic, Merck, Stryker, Thermo Fisher, Zoetis

Sayantani B. Sindher, MD – Speaker
Advisor: DBV Technologies; Consultant: Genentech; Researcher: DBV Technologies, Genentech, Regeneron

Michael E. Wechsler, MD, MMSc – Speaker
Advisor: Allakos, Amgen, Areteia Therapeutics, Arrowhead Pharmaceutical, AstraZeneca, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Equillium, GSK, Incyte, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, Recludix Pharma, Regeneron, Roche/Genentech, Sanofi/Genzyme, Tetherex Pharmaceuticals, Uniquity Bio, Upstream Bio, Verona Pharma, Zurabio
Consultant: Allakos, Amgen, Areteia Therapeutics, Arrowhead Pharmaceutical, AstraZeneca, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Equillium, GSK, Incyte, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, Recludix Pharma, Regeneron, Roche/Genentech, Sanofi/Genzyme, Tetherex Pharmaceuticals, Uniquity Bio, Upstream Bio, Verona Pharma, Zurabio
Researcher: Amgen, AstraZeneca, GSK, Regeneron, Sanofi/Genzyme, Upstream Bio
Speaker: Amgen, AstraZeneca, GSK, Regeneron, Sanofi/Genzyme
Stock/Stock options: Upstream Bio

Kelli Williams, MD, MPH – Speaker
Advisor: Kenota Health; Consultant: ADMA, Amgen, Pharming; Researcher: ADMA, Cogent Biosciences, GSK, Pharming; Speaker: Amgen, Pharming; 

The following have no relevant financial relationships with ineligible companies to disclose:

Karol Anderson – Planner
A. Carmen Choy, MD – Planner
Michelle Huffaker, MD – Planner
Javiad M. Khan – Planner
Steve Machtinger, MD – Moderator, Planner
Sean McGhee, MD, PhD – Planner
Rose Monahan, MD – Planner
Dai Park, MD – Planner
Sarah Pederson, RN – Planner

Available Credit

  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN
Please login or create an account to take this course.